LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 441

Search options

  1. Book ; Online ; E-Book: Nutraceuticals and cardiovascular disease

    Cicero, Arrigo F. G. / Rizzo, Manfredi

    an evidence-based approach for clinical practice

    (Contemporary Cardiology)

    2021  

    Author's details Arrigo F.G. Cicero, Manfredi Rizzo, editors
    Series title Contemporary Cardiology
    Keywords Cardiovascular system/Diseases/Nutritional aspects ; Malalties cardiovasculars ; Dieta
    Subject code 616.10654
    Language English
    Size 1 online resource (301 pages)
    Publisher Humana Press
    Publishing place Cham, Switzerland
    Document type Book ; Online ; E-Book
    Remark Zugriff für angemeldete ZB MED-Nutzerinnen und -Nutzer
    ISBN 3-030-62632-6 ; 3-030-62631-8 ; 978-3-030-62632-7 ; 978-3-030-62631-0
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

  2. Book ; Online: Metformin

    Mihaela Pantea Stoian, Anca / Rizzo, Manfredi

    2020  

    Keywords Pharmacology
    Size 1 electronic resource (242 pages)
    Publisher IntechOpen
    Document type Book ; Online
    Note English ; Open Access
    HBZ-ID HT021049379
    ISBN 9781838807603 ; 1838807608
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    More links

    Kategorien

  3. Article ; Online: The importance of a novel syndemic approach for cardiometabolic diseases.

    Rizzo, Manfredi

    Current medicinal chemistry

    2023  

    Language English
    Publishing date 2023-09-18
    Publishing country United Arab Emirates
    Document type Editorial
    ZDB-ID 1319315-6
    ISSN 1875-533X ; 0929-8673
    ISSN (online) 1875-533X
    ISSN 0929-8673
    DOI 10.2174/0929867331666230918114009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Lipid Guidelines and Cardiovascular Prevention: Let's Manage the Risk of Our Patients!

    Rizzo, Manfredi

    Current pharmaceutical design

    2023  Volume 29, Issue 6, Page(s) 466–467

    MeSH term(s) Humans ; Cardiovascular System ; Heart ; Lipids
    Chemical Substances Lipids
    Language English
    Publishing date 2023-02-04
    Publishing country United Arab Emirates
    Document type Editorial
    ZDB-ID 1304236-1
    ISSN 1873-4286 ; 1381-6128
    ISSN (online) 1873-4286
    ISSN 1381-6128
    DOI 10.2174/1381612829666230220121711
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Molecular Endocrinology and Metabolism in 2021: What's New.

    Rizzo, Manfredi

    International journal of molecular sciences

    2021  Volume 22, Issue 24

    Abstract: The last two years, despite the very serious COronaVIrus Disease-2019 (COVID-19) pandemic, have been quite productive in the field of molecular endocrinology and metabolism and our journal section has contributed extensively on that [ ... ]. ...

    Abstract The last two years, despite the very serious COronaVIrus Disease-2019 (COVID-19) pandemic, have been quite productive in the field of molecular endocrinology and metabolism and our journal section has contributed extensively on that [...].
    MeSH term(s) Endocrine System/metabolism ; Endocrine System/physiology ; Endocrinology/trends ; Humans
    Language English
    Publishing date 2021-12-13
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms222413375
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Cardiovascular and Cardioprotective Agents in 2021.

    Rizzo, Manfredi

    Current pharmaceutical design

    2021  Volume 27, Issue 26, Page(s) 2915–2916

    MeSH term(s) Cardiotonic Agents/pharmacology ; Cardiotonic Agents/therapeutic use ; Cardiovascular Agents ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/prevention & control ; Cardiovascular System ; Humans
    Chemical Substances Cardiotonic Agents ; Cardiovascular Agents
    Language English
    Publishing date 2021-09-15
    Publishing country United Arab Emirates
    Document type Editorial
    ZDB-ID 1304236-1
    ISSN 1873-4286 ; 1381-6128
    ISSN (online) 1873-4286
    ISSN 1381-6128
    DOI 10.2174/138161282726210817124540
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update.

    Caklili, Ozge Telci / Rizzo, Manfredi / Cesur, Mustafa

    Current vascular pharmacology

    2024  

    Abstract: Statins play a significant role in the prevention of cardiovascular (CV) diseases (CVDs); however, non-adherence with statin treatment or statin intolerance (mainly attributed to muscleassociated side effects) is not uncommon. New agents such as ... ...

    Abstract Statins play a significant role in the prevention of cardiovascular (CV) diseases (CVDs); however, non-adherence with statin treatment or statin intolerance (mainly attributed to muscleassociated side effects) is not uncommon. New agents such as bempedoic acid (BA) can provide more treatment options. BA is administered orally, once daily, at a dose of 180 mg in current clinical practice. It can decrease circulating low-density lipoprotein cholesterol (LDL-C) levels by nearly 30% as monotherapy or by 20% as an add-on to statins. CV outcome studies have shown that BA decreases major adverse CV event risk in patients with established CVD or high CV risk by 13%. When patients with high CV risk were analyzed alone, the risk reduction was 30%. Its side effects include a rise in serum uric acid levels and liver enzyme activity, whereas it does not increase diabetes risk as statins do. BA can be used as adjunctive therapy to statins in patients at high CV risk in whom lipid targets cannot be achieved or as an alternative to statins in patients with statin intolerance.
    Language English
    Publishing date 2024-02-07
    Publishing country United Arab Emirates
    Document type Journal Article
    ZDB-ID 2192362-0
    ISSN 1875-6212 ; 1570-1611
    ISSN (online) 1875-6212
    ISSN 1570-1611
    DOI 10.2174/0115701611290763240126045433
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Clinical impact of genetic testing for lipid disorders.

    Muzurović, Emir / Borozan, Sanja / Rizzo, Manfredi

    Current opinion in cardiology

    2024  Volume 39, Issue 3, Page(s) 154–161

    Abstract: Purpose of review: Genetic testing is increasingly becoming a common consideration in the clinical approach of dyslipidemia patients. Advances in research in last decade and increased recognition of genetics in biological pathways modulating blood lipid ...

    Abstract Purpose of review: Genetic testing is increasingly becoming a common consideration in the clinical approach of dyslipidemia patients. Advances in research in last decade and increased recognition of genetics in biological pathways modulating blood lipid levels created a gap between theoretical knowledge and its applicability in clinical practice. Therefore, it is very important to define the clinical justification of genetic testing in dyslipidemia patients.
    Recent findings: Clinical indications for genetic testing for most dyslipidemias are not precisely defined and there are no clearly established guideline recommendations. In patients with severe low-density lipoprotein cholesterol (LDL-C) levels, the genetic analysis can be used to guide diagnostic and therapeutic approach, while in severe hypertriglyceridemia (HTG), clinicians can rely on triglyceride level rather than a genotype along the treatment pathway. Genetic testing increases diagnostic accuracy and risk stratification, access and adherence to specialty therapies, and cost-effectiveness of cascade testing. A shared decision-making model between the provider and the patient is essential as patient values, preferences and clinical characteristics play a very strong role.
    Summary: Genetic testing for lipid disorders is currently underutilized in clinical practice. However, it should be selectively used, according to the type of dyslipidemia and when the benefits overcome costs.
    MeSH term(s) Humans ; Dyslipidemias/diagnosis ; Dyslipidemias/genetics ; Cholesterol, LDL ; Lipids ; Hypertriglyceridemia/diagnosis ; Hypertriglyceridemia/genetics ; Genetic Testing
    Chemical Substances Cholesterol, LDL ; Lipids
    Language English
    Publishing date 2024-02-29
    Publishing country United States
    Document type Review ; Journal Article
    ZDB-ID 645186-x
    ISSN 1531-7080 ; 0268-4705
    ISSN (online) 1531-7080
    ISSN 0268-4705
    DOI 10.1097/HCO.0000000000001133
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Exploring the Landscape of Familial Hypercholesterolemia: Unraveling Genetic Complexity and Clinical Implications.

    Barkas, Fotios / Liberopoulos, Evangelos / Rizzo, Manfredi

    European journal of internal medicine

    2024  Volume 123, Page(s) 58–59

    MeSH term(s) Humans ; Hyperlipoproteinemia Type II/genetics ; Receptors, LDL/genetics ; Mutation ; Cholesterol, LDL/blood ; Proprotein Convertase 9/genetics
    Chemical Substances Receptors, LDL ; Cholesterol, LDL ; Proprotein Convertase 9 (EC 3.4.21.-)
    Language English
    Publishing date 2024-03-04
    Publishing country Netherlands
    Document type Letter ; Journal Article
    ZDB-ID 1038679-8
    ISSN 1879-0828 ; 0953-6205
    ISSN (online) 1879-0828
    ISSN 0953-6205
    DOI 10.1016/j.ejim.2024.02.031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction.

    Rizvi, Ali A / Rizzo, Manfredi

    Diabetes, metabolic syndrome and obesity : targets and therapy

    2022  Volume 15, Page(s) 1023–1030

    Abstract: The incretin pathway is a self-regulating feedback system connecting the gut with the brain, pancreas, and liver. Its predominant action is on the postprandial glucose levels, with extraglycemic effects on fat metabolism and endovascular function. Of the ...

    Abstract The incretin pathway is a self-regulating feedback system connecting the gut with the brain, pancreas, and liver. Its predominant action is on the postprandial glucose levels, with extraglycemic effects on fat metabolism and endovascular function. Of the two main incretin hormones released with food ingestion, the actions of glucagon-like peptide-1 (GLP-1) have been exploited for therapeutic benefit. However, little attention has been paid to glucose-dependent insulinotropic polypeptide (GIP) until the recent experimental introduction of dual agonists, or "twincretins". Interestingly, simultaneous activation of both receptors is not only replicative of normal physiology, it seems to be an innovative way to enhance their mutual salubrious actions. In patients with type 2 diabetes, dual agonists can have powerful benefits for glucose control and weight reduction. Additionally, there is mounting evidence of their favorable cardiovascular impact, making them potentially appealing pharmacologic agents of choice in the future. Although we seem to be poised on the horizons of exciting new breakthroughs, much knowledge has yet to be gained before these novel agents are ready for prime time.
    Language English
    Publishing date 2022-04-05
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2494854-8
    ISSN 1178-7007
    ISSN 1178-7007
    DOI 10.2147/DMSO.S351982
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top